Trial Profile
Double-blind, placebo-controlled, parallel group study to evaluate safety and efficacy of oral fampridine-SR (10 mg b.i.d.) in patients with multiple sclerosis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Feb 2016
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- 25 Apr 2012 Results presented at the 64th Annual Meeting of the American Academy of Neurology, according to an Acorda Therapeutics media release.
- 27 Feb 2012 Primary endpoint changed as reported by ClinicalTrials.gov (Extention trial NCT00649792).
- 27 Feb 2012 Primary endpoint changed as reported by ClinicalTrials.gov (Extention trial NCT00649792).